Vitekta (elvitegravir) / Japan Tobacco, Gilead - LARVOL DELTA

Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species. (PubMed, PLoS One) - "From this hit set, we prioritized the two FDA-approved HIV drugs, cobicistat and elvitegravir, as promising lead candidates. These combinations also disrupted mature biofilms, achieving up to 80% eradication, a substantial improvement over AmB alone. These findings highlight the potential of these drug combinations as promising treatment options for aspergillosis, leveraging already approved therapies."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. (PubMed, J Antimicrob Chemother) - "This study provides a systematic framework for evaluating post-marketing AEs of INSTIs and NNRTIs using a semi-quantitative scoring system. Our findings identified five high-priority AEs that require clinical validation and further investigation."

Adverse events • Journal • Eosinophilia • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. (PubMed, HIV Med) - "This study identified metabolic AEs associated with INSTIs, with agent-specific differences in risk and timing, highlighting the need for regular monitoring and individualized management during INSTI-based ART."

Adverse events • Journal • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China. (PubMed, BMC Infect Dis) - "INSTI-based ART was associated with sustained weight gain but did not worsen long-term dyslipidemia compared to an EFV-based regimen in a real-world setting. Hepatic steatosis correlated with metabolic parameters rather than INSTI exposure."

Journal • Real-world evidence • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable. (PubMed, J Antimicrob Chemother) - "Although the use of INSTIs has increased over time with differences in the duration of use, we did not observe a corresponding increase in the proportion of ARV-treated PLWHIV who experienced virological failure with INSTI-resistant viruses during the study period."

Journal • Human Immunodeficiency Virus • Infectious Disease

Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infection. (PubMed, J Infect Dis) - "Here, we show that the same inserts provide significant post-exposure protection (82.9% efficacy) when applied four hours after SHIV exposure. Our findings further support the ongoing clinical development of TAF/EVG inserts for on-demand HIV prevention."

Journal • Human Immunodeficiency Virus • Infectious Disease

Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: a global individual patient data meta-analysis. (PubMed, Emerg Microbes Infect) - "IPD analysis of 394 mutation-positive individuals revealed 8.52% low-frequency resistance to dolutegravir and bictegravir in treatment-naïve populations, while treated patients exhibited significantly increased intermediate/high-level resistance to first-generation INSTIs, including raltegravir and elvitegravir. Although second-generation INSTIs maintain lower resistance rates, cross-resistance risks necessitate clinical vigilance. Optimized resistance surveillance strategies incorporating low-frequency mutation detection offer critical evidence for advancing global HIV control efforts."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Curcumin-enhanced elvitegravir therapy mitigates neuroinflammation and cognitive deficits in EcoHIV mice. (PubMed, Exp Biol Med (Maywood)) - "These findings demonstrate that the EVG + CUR combination effectively targets both viral persistence and the underlying neuroinflammatory and oxidative mechanisms driving HAND. By improving cognitive and motor function while mitigating neuroinflammation and oxidative stress, EVG + CUR represents a promising adjunctive therapy for HAND, offering a multifaceted approach to addressing the complex pathophysiology of HIV-associated neurocognitive disorders."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Developmental Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • IL1B • IL6 • TNFA

Prevalence of primary HIV-1 drug resistance among antiretroviral-naïve individuals in Togo in 2023: a national study. (PubMed, Front Public Health) - "However, accessory mutations (genetic changes that do not confer significant resistance by themselves) as E157Q/E157EQ (43/57) and T97A/T97TA (14/57) associated with resistance against first-generation integrase inhibitors (INIs) as raltegravir, elvitegravir were found in 17.2% of samples. The dominant subtypes were CRF02_AG (64.8%) and CRF06_cpx (12.8%). These results support the continued use of dolutegravir-based regimens in Togo and call for continued monitoring of primary resistance to maintain the effectiveness of therapeutic strategies in Togo."

Journal • Human Immunodeficiency Virus • Infectious Disease

A Rare Case of Diffuse Esophageal Intramural Pseudodiverticulosis! (ACG 2025) - "Medications included a combination of elvitegravir, cobicistat, emtracitibine, and tenofovir alafenamide in addition to colchicine and atorvastatin. Management aims at controlling the underlying inflammation, relieving the patients' symptoms and treating the coexisting esophageal conditions. Despite that EIPD is considered a benign clinical entity, serious complications can occur including esophageal stricture, esophageal dysmotility, esophageal perforation, intra-mediastinal fistula, mediastinitis, and lung abscess.Figure: Esophageal Intramural Pseudo-DiverticulosisFigure: Pathology"

Clinical • Candidiasis • CNS Disorders • Depression • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Gout • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Inflammatory Arthritis • Psychiatry • Rheumatology • CD4

Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes. (PubMed, Clin Infect Dis) - "Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae."

Journal • Human Immunodeficiency Virus • Infectious Disease • Obesity • Pediatrics • CD4

Differences in ART regimen initiation among people with recently acquired HIV: 2015-2021 (EACS 2025) - "INSTIs were classified as first-generation (raltegravir, elvitegravir) or second-generation (dolutegravir, bictegravir). However, women and individuals from Africa remain less likely to receive these regimens despite early care engagement. Qualitative research with prescribers is needed to understand these disparities to inform more equitable ART initiation."

Human Immunodeficiency Virus • Infectious Disease • CD4

Nucleocapsid mutations at time of virological failure with an integrase inhibitor (EACS 2025) - "Results : Sequences were available for 61 PLWH-1 receiving either elvitegravir (n=3), raltegravir (n=4), cabotegravir (n=4), dolutegravir (n=18), or bictegravir (n=32). Conclusions : Our study confirms that mutations in the nucleocapsid are observed in a small number of individuals with VF with an INSTI-based regimen. Phenotypic data are needed to decipher the impact of the new mutations (F16Y, N27D, and N27H), and the frequency of nucleocapsid mutations should be explored in larger cohorts."

Human Immunodeficiency Virus • Infectious Disease

Integrated Population Pharmacokinetic-pharmacodynamic Modeling of HIV Virus-host Infection Dynamics in Patients Undergoing Antiretroviral Monotherapy. (PubMed, AAPS J) - "This work aims to develop a single and fully identifiable population semi-mechanistic pharmacokinetic/pharmacodynamic (popPKPD) model integrating data (drug levels, CD4 + T cells and viral RNA) of five different antiretroviral (ARV) drugs administered in monotherapy: lenacapavir, bictegravir, tenofovir alafenamide, emtricitabine and elvitegravir. The popPKPD model was able to capture key aspects of viral dynamics, drug behaviour, and treatment response. The models developed will serve as a useful tool for further development and optimization of these HIV therapies, especially when evaluating multiple ARVs to be administered in a novel combination setting."

Journal • Monotherapy • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • CD4

Talaromyces Marneffei Infection Involving the Central Nervous System in a Patient with Acquired Immunodeficiency Syndrome: A Case Report and Literature Review. (PubMed, Int J Infect Dis) - "CNS Talaromyces marneffei infection in AIDS patients often lacks specific clinical manifestations, which complicates diagnosis and treatment. This case report contributes to the existing body of knowledge by presenting a successfully managed case, thereby enhancing the understanding of diagnostic and therapeutic strategies for similar future presentations."

Journal • Review • CNS Disorders • Dermatology • Epilepsy • Human Immunodeficiency Virus • Infectious Disease

Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study. (PubMed, BMC Med) - P3 | "Both ISG and DSG maintained high viral Suppression in PLWH through 96 weeks. DSG could offset weight gain and dyslipidemia associated with previous exposure to E/C/F/TAF."

Clinical • Journal • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Psychiatry

Prevalence of acquired resistance to HIV integrase strand transfer inhibitors (INSTIs) in clinical samples from treatment-experienced patients in Chile, 2012-2023. (PubMed, J Virus Erad) - "High AR rates were observed for first-generation INSTIs: raltegravir (28 %) and elvitegravir (27.7 %). Lower resistance levels were found for dolutegravir (8.3 %), bictegravir (8.3 %), and cabotegravir (18.7 %)...These findings highlight the need for nationwide molecular surveillance and pre-treatment genotyping, particularly before initiating long-acting regimens such as CAB-LA. Strategic monitoring will be critical to maintaining the efficacy of current and next-generation INSTIs."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Confronting Dual Therapeutic Hurdles in Advanced HIV: A Case Report on INSTIs Resistance and Talaromyces marneffei Coinfection. (PubMed, Int Med Case Rep J) - "Antiretroviral therapy (ART) was switched from elvitegravir to zidovudine, lamivudine, dolutegravir, and albuvirtide. Antifungal therapy adjusted from voriconazole to itraconazole...This case emphasizes genotype resistance testing-guided ART modification and rigorous opportunistic infection management in drug-resistant HIV patients. Coordinated care and timely interventions can enhance the outcomes in high-risk cases."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study - IMEA 057. (PubMed, J Infect Public Health) - "The findings indicate that B/F/TAF is both safe and effective for elderly PWH patients with a prolonged and documented history of HIV infection, multiple co-morbidities and concomitant medication."

Journal • Cardiovascular • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Psychiatry

Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study. (PubMed, J Infect Dis) - "In PWH from Switzerland, untargeted metabolite profiling revealed multiple unreported associations with different ART agents, and previously reported associations with BMI."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Exploring the Potential of HIV Integrase Inhibitors as Therapeutic Agents Against HSV and HCMV: A Molecular Docking Study. (PubMed, J Exp Pharmacol) - "Among the anti-HIV drugs tested, Elvitegravir and raltegravir were most effective in controlling the HSV-1 and HSV-2 infections at concentrations as low as 1.6 µg/mL when tested with 10TCID50 viral challenge dose. The tested FDA approved drug molecules showed the potential to be repurposed as an antiHSV and antiHCMV agent. The in silico and in vitro results warrant further investigation in preclinical and clinical studies to validate its therapeutic potential and safety for HSV-related infections."

Journal • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease

High-performance hairpin-whiptail DNA target for HIV-1 integrase assay. (PubMed, Int J Biol Macromol) - "The hairpin-whiptail target DNA yielded an excellent Z' score of 0.758 with the qPCR-based integrase activity assay making it suitable for screening compound libraries and determination of IC50 as demonstrated with elvitegravir. While the hairpin-whiptail target DNA was specifically designed for the qPCR integrase activity assay, it could easily be adapted to improve the performance of other integrase assays."

Journal • Human Immunodeficiency Virus • Infectious Disease

Comparative effectiveness of modern antiretroviral therapy regimens among people living with HIV in China: a multicenter cohort study (IAS-HIV 2025) - "Most frequently used third ART drugs included nevirapine, efavirenz, dolutegravir, lopinavir, and others (including darunavir, raltegravie, elvitegravir and rilpivirine). Our findings further reinforce the positioning of dolutegravir-based regimens as preferred options in LMICs."

Clinical • HEOR • Human Immunodeficiency Virus • Infectious Disease • CD4

HIV-1 Genetic Diversity and Transmitted Drug Resistance Mutations in ART-Naïve Individuals in South Korea from 2021 to 2024. (PubMed, Viruses) - "The integrase strand transfer inhibitor drugs, elvitegravir and raltegravir, most frequently exhibited high resistance scores. We provide a comprehensive overview of the HIV-1 genetic distribution and TDR patterns in South Korea from 2021 to 2024. Within the broader context of HIV-1 epidemiology in Asia and the Pacific, the findings contribute to a comprehensive understanding of the global distribution of HIV-1 resistance and genotypes, enabling the development of effective interventions."

Journal • Human Immunodeficiency Virus • Infectious Disease

METTL3-Driven m6A Modifications in Esophageal Squamous Cell Carcinoma: Emerging Mechanisms, Biomarker Potential, and Therapeutic Innovations. (PubMed, Eur J Pharmacol) - "Emerging therapeutic strategies targeting METTL3, including small-molecule inhibitors [e.g., Elvitegravir] and RNA-based interventions, demonstrate preclinical efficacy in suppressing ESCC proliferation and metastasis. This review also identifies critical knowledge gaps, such as the interplay between METTL3 and tumor microenvironment dynamics, and advocates for multicenter studies to validate its clinical applicability. Collectively, our findings position METTL3 as a promising biomarker and a tractable therapeutic target, offering actionable insights to advance ESCC management."

Biomarker • Journal • Review • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • EGR1 • METTL3 • SLC2A1